Osaterone acetate

• Description :

  Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H361

• Target :

  5 alpha Reductase; Androgen Receptor

• Related Pathways :

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research :

  Endocrinology

• Smiles :

  CC(O[C@]1([C@@]2([C@@]([C@@]3([H])[C@]([C@@]4(C(C(Cl)=C3)=CC(OC4)=O)C)([H])CC2)([H])CC1)C)C(C)=O)=O

• Molecular Formula :

  C22H27ClO5

• Molecular Weight :

  406.90

• Precautions :

  P264-P270-P280-P330-P405-P501

• References & Citations :

  [1]Niżański W, et al. Comparison of Clinical Effectiveness of Deslorelin Acetate and Osaterone Acetate in Dogs with Benign Prostatic Hyperplasia. Animals (Basel) . 2020 Oct 21;10 (10) :1936.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [105149-00-6]